CAMBRIDGE, Mass., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. MCRB (Seres or the Company), a leading live biotherapeutics company, announced today the receipt of a $50 million installment payment related to the Company's previously announced sale of its VOWST business to Société des Produits Nestlé S.A (SPN, and with certain of its affiliates, collectively, Nestlé Health Science). This installment payment was expected as Seres is fulfilling its transition obligations. As previously announced, based on the Company's existing cash, inclusive of this payment, a projected installment payment from Nestlé Health Science in July 2025 of $25 million (less up to approximately $1.5M in employment-related payments to Nestlé Health Science), transaction-related obligations and current operating plans, the Company expects to fund operations into the first quarter of 2026. About Seres Therapeutics  Seres Therapeutics, Inc. MCRB is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics

Hensley joins from Seres Therapeutics, where she served as senior vice president, assistant general counsel and chief compliance officer, overseeing corporate legal and compliance matters.